HC Wainwright set a $6.00 price target on Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research note issued to investors on Sunday, May 13th. The brokerage currently has a buy rating on the biotechnology company’s stock.
Several other analysts have also issued reports on APTO. ValuEngine upgraded shares of Aptose Biosciences from a sell rating to a hold rating in a report on Tuesday, May 8th. Zacks Investment Research lowered shares of Aptose Biosciences from a buy rating to a hold rating in a report on Monday, April 16th. Finally, Roth Capital set a $6.00 price objective on shares of Aptose Biosciences and gave the company a buy rating in a report on Monday, April 16th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the stock. The stock presently has an average rating of Hold and a consensus price target of $5.63.
Shares of NASDAQ APTO traded up $0.06 during trading on Friday, hitting $3.50. 100 shares of the company were exchanged, compared to its average volume of 370,757. Aptose Biosciences has a 12-month low of $1.00 and a 12-month high of $3.97. The firm has a market cap of $113.18 million, a PE ratio of -6.62 and a beta of 2.38.
A hedge fund recently bought a new stake in Aptose Biosciences stock. Ladenburg Thalmann Financial Services Inc. acquired a new position in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 60,000 shares of the biotechnology company’s stock, valued at approximately $190,000. Ladenburg Thalmann Financial Services Inc. owned approximately 0.19% of Aptose Biosciences as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 1.54% of the company’s stock.
Aptose Biosciences Company Profile
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.